A method of preventing rejection of an implant in the eye, includes forming a flap in the cornea of the eye, inserting an implant under the flap, cross linking corneal tissue surrounding an implant to make the corneal tissue surrounding an implant less vulnerable to enzymatic degradation, inserting polymeric material under the corneal flap so as to overlie corneal tissue, compressing a layer of the cornea from outside using a lens having a predetermined curvature to correct refractive error of the cornea, and cross linking corneal tissue that the polymeric material overlies.

The present invention relates to a method of altering the refractive properties of the eye, the method including applying a substance to a cornea of an eye, the substance configured to facilitate cross linking of the cornea, irradiating the cornea so as to activate cross linkers in the cornea, and altering the cornea so as to change the refractive properties of the eye.

An ophthalmic assembly includes a frame, flange, and light emitter. The frame supports an optical lens. A first end of the flange is connected to the frame. A second end of the flange rests on a pars plana region of the sclera of a patient's eye. The light emitter is connected to the flange proximate the second end to direct light into a vitreous cavity of the patient's eye. This occurs through the sclera at the pars plana region and uniformly illuminates the vitreous. A transscleral illumination system includes the ophthalmic assembly and a processor in communication with the light emitter. A setting of the light emitter may be controllable via the processor, e.g., in response to a user input signal.

A system for the treatment of the dry eye syndrome that is based on a light source. The system includes a disposable tip, to treat an eyelid. A corneal shield is used to protect the patient's eye.

A source of light energy such as a source of violet light energy is coupled to a structure configured to contact the eye. The light source and structure are arranged to provide therapeutic amounts of violet light energy to the eye in order to inhibit the progression of refractive error such as myopia. The light source can be configured in many ways and may comprise a radioisotope and a phosphorescent material. The structure configured to contact the eye may comprise a contact lens or an implant.

A contact lens for cornea-correction crosslinking made of an ultraviolet transmitting material includes, on a cornea contact side, a pressing region projecting in a convex curved-surface shape at a position corresponding to the center of a corneal dome to be pressed and a relief region constituted by an annular concave portion in a circular arc shape, encircling the outer periphery of the pressing region. The contact lens corrects at least naked eye vision or keratoconus cornea by pressing both regions to the cornea and changing its shape. The contact lens includes a reservoir portion outside the pressing region in a lens thickness direction for a riboflavin solution, a communication hole communicating the reservoir portion inside with the pressing region, and an operation-side electrode having the same polarity as that of the riboflavin solution. The mounted contact lens allows riboflavin solution infiltration into corneal tissue by iontophoresis and ultra-violet ray irradiation.

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

An ophthalmic treatment system is configured to perform scanning of target tissue in a patient's eye to at least visualize the target tissue. The scanning pivots about a patient's iris to scan a retina.

An ophthalmic phototherapy device and associated phototherapy treatment method for promoting healing of damaged or diseased eye tissue. The ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue. The ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.

An ophthalmic phototherapy device and associated phototherapy treatment method for promoting healing of damaged or diseased eye tissue. The ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue. The ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.